Companies in #Facioscapulohumeral Muscular Dystrophy (FSHD)
Found 2 companies operating in this sector.
Avidity Biosciences is a biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™) designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapeutics to target previously untreatable genetic muscle disorders. Founded in 2012 and headquartered in San Diego, California, Avidity was acquired by Novartis AG in early 2026 for approximately $12 billion to strengthen Novartis' late-stage neuroscience and RNA medicines pipeline. In late 2026, following a $1.9 billion impairment charge recorded by parent company Novartis on lead Phase 3 myotonic dystrophy type 1 (DM1) candidate del-desiran (AOC 1001), Avidity filed a California WARN Act notice eliminating 40 positions (~8% of workforce) across clinical operations, medical writing, and regulatory affairs on a rolling basis beginning December 31, 2026.
Bionano Genomics develops optical genome mapping systems and genome analysis software used by cytogenetics and molecular genetics laboratories to detect structural variants that sequencing and microarrays routinely miss. Its Saphyr and Stratys instruments, Saphyr chips, DNA labeling and prep kits, Ionic purification system and VIA analysis software form a sample-to-result workflow, complemented by laboratory testing services that include OGM-Dx HemeOne for hematologic neoplasms, OGM-Dx FSHD, Fragile X testing, and chromosomal microarray and exome panels for developmental disorders. The company's reimbursement profile widened in September 2026, when wholly owned subsidiary Bionano Laboratories announced a proposed MolDX local coverage determination for genome-wide detection of copy-number alterations and structural variants in hematologic neoplasms, alongside a New York State approval of its clinical offering.